Australia Cell & Gene Therapy Bioanalytical Testing Services Market Size & Outlook
Australia cell & gene therapy bioanalytical testing services market, 2018-2030 (US$M)
Related Markets
Australia cell & gene therapy bioanalytical testing services market highlights
- The Australia cell & gene therapy bioanalytical testing services market generated a revenue of USD 18.9 million in 2023 and is expected to reach USD 31.0 million by 2030.
- The Australia market is expected to grow at a CAGR of 7.3% from 2024 to 2030.
- In terms of segment, bioavailability & bioequivalence studies was the largest revenue generating test type in 2023.
- Bioavailability & Bioequivalence Studies is the most lucrative test type segment registering the fastest growth during the forecast period.
Cell & gene therapy bioanalytical testing services market data book summary
| Market revenue in 2023 | USD 18.9 million |
| Market revenue in 2030 | USD 31.0 million |
| Growth rate | 7.3% (CAGR from 2023 to 2030) |
| Largest segment | Bioavailability & bioequivalence studies |
| Fastest growing segment | Bioavailability & Bioequivalence Studies |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Bioavailability & Bioequivalence Studies, Pharmacokinetics, Pharmacodynamics, Other test type |
| Key market players worldwide | IQVIA Holdings Inc, Labcorp Holdings Inc, Thermo Fisher Scientific Inc, Pharmaron Beijing Co Ltd Ordinary Shares - Class H, Charles River Laboratories International Inc, Syneos Health, Intertek Group PLC |
Other key industry trends
- In terms of revenue, Australia accounted for 3.7% of the global cell & gene therapy bioanalytical testing services market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan cell & gene therapy bioanalytical testing services market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 59.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cell & Gene Therapy Bioanalytical Testing Services Market Scope
Cell & Gene Therapy Bioanalytical Testing Services Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Australia cell & gene therapy bioanalytical testing services market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell & gene therapy bioanalytical testing services market will help companies and investors design strategic landscapes.
Bioavailability & bioequivalence studies was the largest segment with a revenue share of 35.45% in 2023. Horizon Databook has segmented the Australia cell & gene therapy bioanalytical testing services market based on bioavailability & bioequivalence studies, pharmacokinetics, pharmacodynamics, other test type covering the revenue growth of each sub-segment from 2018 to 2030.
Australia is considered to have one of the best healthcare systems in the world. The increasing awareness about the need for early detection of lifestyle and the rising prevalence of chronic diseases are expected to boost the market in the country.
Several companies in Australia offer bioanalytical testing services for cell and gene therapies. Some key players are Covance (Labcorp), Novotech, Cancer Therapeutics CRC, and others. Canthera Discovery is a renowned cancer research company that specializes in the development and discovery of small-molecule drugs.
To bridge the gap between fundamental research and practical applications, it collaborates with top Australian research organizations, academic institutions, and biotechnology companies. With a proven track record of success, Canthera Discovery has carried out preclinical licensing agreements and research partnerships with global pharmaceutical corporations, bringing millions of dollars in revenue to the Australian biomedical sector.
Reasons to subscribe to Australia cell & gene therapy bioanalytical testing services market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Australia cell & gene therapy bioanalytical testing services market databook
-
Our clientele includes a mix of cell & gene therapy bioanalytical testing services market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia cell & gene therapy bioanalytical testing services market , including forecasts for subscribers. This country databook contains high-level insights into Australia cell & gene therapy bioanalytical testing services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Australia cell & gene therapy bioanalytical testing services market size, by test type, 2018-2030 (US$M)
Australia Cell & Gene Therapy Bioanalytical Testing Services Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
